BRCA2 and cancer: cfDNA sequencing using MSK-ACCESS, an ultra-high coverage NGS panel that includes exons from 129 cancer-associated genes, including all exons of BRCA2, did not detect any resistance mechanism compared to baseline cfDNA30.